Terns Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, announced that it has granted equity inducement awards to two new employees as part of its 2022 Employment Inducement Award Plan. Approved by the Compensation Committee of the Board of Directors, these awards comply with Nasdaq Listing Rule 5635(c)(4). The new employees have been granted options to purchase a total of 325,000 shares of Terns common stock. These options, with a 10-year term, carry an exercise price of $3.56 per share, corresponding to the closing price on May 1, 2025. The vesting schedule spans four years, contingent upon the employees' continued service.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。